are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial. OBJECTIVE: To compare the effectiveness, complications, and costs of UFH and LMWH as VTE ...
As part of the initial quality improvement project, the group analyzed factors associated with and rates of hospital-acquired VTE. Among the findings was a predominance of hospital-acquired VTE ...
The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...
Sam Mercer, from Crosby, broke his leg in December 2023 and on Valentine's Day, underwent surgery to fix the problem. The ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
In a large, real-world analysis of United States Medicare fee-for-service patients, Ferro et al found that inferior vena cava ...
A recent review in Cureus outlines surgical cosmetic procedures after weight loss, educating clinicians in counseling ...
Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
VTE events with and without VTE prophylaxis during NACT. Characteristics No VTE Prophylaxis N=184 (63.4%) VTE Prophylaxis N=106 (36.5%) p-value ...
selecting the duration of warfarin therapy for prophylaxis of recurrence of VTE, and adjusting the dosage of warfarin for prevention of haemorrhage complications.